Abciximab provides cost-effective survival advantage in high-volume interventional practice

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Health Economics

Background:

• Platelet glycoprotein (GP) IIb/IIIa inhibitors are effective in reducing ischemic events during percutaneous coronary intervention (PCI).
• The cost-effectiveness of GP IIb/IIIa blockade as adjunctive therapy in PCI remains a subject of scrutiny.
• Extrapolating trial-based cost-efficacy data to real-world practice presents challenges.

Purpose of the Study:

• To evaluate the cost-effectiveness of abciximab therapy in a real-world setting of percutaneous coronary intervention.
• To assess the impact of abciximab on procedural and long-term (6-month) survival and healthcare charges.
• To identify patient and procedural characteristics associated with improved cost-effectiveness.

Main Methods:

• Analysis of 1472 consecutive percutaneous coronary interventions performed in 1997.
• Utilized propensity scoring methods to adjust for nonrandomized abciximab allocation.
• Evaluated procedural outcomes, 6-month survival rates, and associated healthcare charges.

Main Results:

• Abciximab therapy demonstrated a survival advantage at 6 months post-PCI, with adjusted mortality reduction of 4.9%.
• The adjusted average charge increment associated with abciximab was $950 over 6 months.
• The adjusted cost per life-year gained was favorable at $1243, particularly in patients with multivessel intervention, stent deployment, recent myocardial infarction, or impaired left ventricular function.

Conclusions:

• Abciximab provides a cost-effective survival benefit in high-volume interventional cardiology practice.
• The therapy's cost-effectiveness favorably compares to established standards of care.
• Multivessel intervention, stent use, recent myocardial infarction, and impaired left ventricular function are associated with enhanced cost-effectiveness.